In 2026, new and recently updated US psilocybin assisted therapy trials are testing psilocybin with structured psychological support for conditions that include major depression, alcohol-related outcomes and anorexia nervosa.
What conditions are being studied right now
Psilocybin assisted therapy trials in the US keep a tight focus on specific diagnoses and clearly defined outcomes. That makes it easier to compare results across participants, track safety in a consistent way and understand who might benefit in later phases of research. Trial listings also show that researchers are still testing core questions that are practical for real participants, like how long effects last, how many sessions are used and what kinds of follow-ups are needed.
Depression
Depression remains one of the most active areas for psilocybin assisted therapy trials in the US. Current listings include studies that compare a single psilocybin dose to placebo, track changes in depression scales after dosing and follow participants for durability of effect across weeks or longer.
If you are looking at depression trial listings in 2026, you will often see details like these.
- A baseline period to confirm symptoms remain stable enough to measure change
- One dosing day with supervised monitoring and psychological support
- Follow-up visits that include symptom scales and safety checks across several weeks
- Longer follow-up periods in some trials to track durability and any delayed adverse effects
Many depression trials also use structured therapy sessions around dosing. The language may vary between listings, but the idea is consistent. You meet the clinical team ahead of time, you prepare for the dosing day, you complete the dosing day with supervision, then you return for integration sessions and outcome assessments.
Alcohol-related outcomes
Trials focused on alcohol-related outcomes often look at drinking patterns, craving, heavy drinking days or related clinical measures. Some protocols pair psilocybin with psychotherapy and track alcohol outcomes over a defined follow-up window.
If you are considering one of these studies, expect trial teams to take substance use safety seriously. You may see requirements around current use, withdrawal risk, medication interactions and stability in mental health symptoms. That tends to show up in screening and eligibility steps, and it often continues through follow-up planning after dosing.
Anorexia nervosa
Anorexia nervosa is another active area in current US listings, including trials in young adults that combine psilocybin with psychological support and evaluate safety along with changes in symptoms or related measures.
If you are living with anorexia nervosa, trial participation can include extra layers of medical review compared to some other indications. That can mean closer attention to weight stability, cardiac risk, lab results, current level of care and the safety of participating without destabilizing nutrition support. The specifics depend on the protocol, but you should expect medical screening to be more detailed than a short interview.
What participation usually involves
Trials vary by condition, dose, number of dosing sessions and follow-up length. Still, many protocols share a common pattern that you can use to set expectations. The FDA has also published a draft guidance focused on clinical investigations of psychedelic drugs, and that guidance reflects the practical realities you will often see in protocols, like attention to set and setting, psychological support and safety monitoring.
Screening and eligibility
Screening is usually the longest part before you ever receive a dose. It is also where many applicants learn they are not eligible. That can feel frustrating, but eligibility rules exist because trial teams have to manage safety risk and study validity at the same time.
Common screening elements include these.
- A diagnostic interview to confirm the target condition
- A review of your treatment history and current symptoms
- Medication review for interaction risk and washout requirements when applicable
- Medical history, physical exam and sometimes ECG or lab work
- Assessment of psychosis history, bipolar history or current instability, since many protocols exclude these risks
- Substance use review, which can be especially detailed in alcohol-focused studies
You will also see practical criteria that are not about diagnosis. Some trials require a support person for transport home after dosing. Some require that you can attend multiple weekday visits. Some limit travel distance because follow-ups need to happen on a schedule.
If you are searching for trials, trial listings on ClinicalTrials.gov often show key inclusion and exclusion criteria, outcomes measured and an estimated visit timeline. You should read the listing like a contract. Look for the time commitment, the number of visits and any requirements around therapy sessions, medication changes or abstinence from substances.
Prep sessions
Preparation sessions are usually a mix of practical orientation and therapeutic groundwork. You build rapport with the study team, you review what the dosing day may feel like, and you discuss how you tend to respond to stress and uncertainty.
Prep sessions often cover topics like these.
- What you want from participating and what a trial can and cannot promise
- How to work with difficult thoughts, fear or intense emotions during dosing
- What the room setup and monitoring will look like
- How music, eyeshades or guided attention may be used in that protocol
- Safety rules around leaving the site, driving and post-session contact
In one well-known randomized trial design for major depressive disorder, participants completed preparatory meetings totaling about 8 hours before dosing, then returned for follow-up and integration work. Your study may use more or fewer hours, but this gives you a real-world reference point for the level of preparation a modern protocol can include.
Preparation is also where you should ask direct questions. Ask what happens if you panic. Ask how the team responds if you want to stop. Ask how they handle sleep problems after dosing. Ask what kind of after-hours support is available in the days right after the session.
Dosing session day
The dosing day is usually the longest single visit. Many protocols plan for most of the day on site, often around 6 to 8 hours, sometimes longer depending on assessments and how you are doing after the acute effects pass.
On dosing day, you can usually expect these features.
- A check-in and baseline symptom and safety measures
- Confirmation of recent substance use rules and any medication requirements
- A supervised dosing period in a controlled room
- Continuous or frequent monitoring of safety signals like blood pressure and heart rate
- Support from trained monitors or clinicians during the acute period
- A discharge plan that confirms you are stable, oriented and safe to leave with your arranged transport
Your subjective experience can vary widely. Some participants report calm and clarity. Some report fear, grief, shame or vivid autobiographical material. Many report a mix across the same session. Trials prepare for this range because the experience itself can be intense even when safety is managed well.
You should also expect rules that protect study integrity. The team may limit phone use. The team may limit contact with people outside the study during the acute session. The team may ask you not to discuss certain details with other participants if the study includes blinding.
Integration and follow-ups
Integration sessions are where you process what happened and connect it to behavior, relationships and symptom patterns. In trials, integration also serves a safety role. It gives the team a structured chance to check on your mood, sleep, anxiety and functioning after the acute effects.
Follow-ups usually include both clinical assessments and safety monitoring.
- Symptom scales for the target condition
- Adverse event checks and medical checks as required
- Interviews about drinking patterns in alcohol-related studies
- Longer follow-up windows in some trials to track durability and relapse patterns
A key practical point is the timing. Many protocols schedule follow-ups tightly in the first days and weeks after dosing, then space them out. You should plan your calendar around the protocol, not around your best guess. If you cannot meet the visit schedule, you may not be eligible.
If you want a reference for what follow-up can look like in a modern protocol, the major depressive disorder trial in JAMA Psychiatry included structured preparation, a monitored dosing session and follow-up assessments across weeks, which is consistent with how many current studies are designed.
What outcomes trials tend to measure
Outcome measures depend on the condition being studied, the study phase and what the investigators are trying to prove.
For depression trials, outcomes commonly include validated depression symptom scales rated by clinicians or self-report scales completed by you. Trials often define a primary endpoint at a specific time point after dosing, then measure durability at later visits. (clinicaltrials.gov)
For alcohol-related outcomes, trials may measure drinking days, heavy drinking days, craving measures and other substance use related metrics. They may also track mood and anxiety changes because these can relate to drinking patterns and relapse risk. (clinicaltrials.gov)
For anorexia nervosa trials, outcomes can include safety endpoints, eating disorder symptom measures and related psychological outcomes that the protocol defines in advance. Because medical risk can be higher in this population, safety outcomes can take a central role in the design. (clinicaltrials.gov)
Across indications, you will also see outcomes tied to function and quality of life, sleep, anxiety symptoms and measures of suicidality monitoring when relevant. The FDA draft guidance highlights the need for careful safety monitoring and thoughtful trial design in psychedelic clinical investigations, which supports why these outcomes and monitoring practices appear so frequently. (U.S. Food and Drug Administration)
When you read a trial listing, look for three practical details.
- The primary outcome and the exact time point it is measured
- The follow-up length, since short follow-up can miss relapse or delayed adverse events
- The type of psychological support, since protocols vary a lot in how therapy is delivered (clinicaltrials.gov)
Risks, safeguards and follow-up planning
Psilocybin trials are designed around risk management. Risks can come from the acute psychoactive experience, from medical effects like transient increases in blood pressure and heart rate and from the psychological after-effects that can unfold over days or weeks.
Common acute side effects reported in clinical contexts include headache, nausea, dizziness, fatigue and transient anxiety. Some participants have intense fear or agitation during the session that requires skilled support and monitoring.
Trials manage these risks through protocol safeguards that you will see reflected in the study flow.
- Exclusion criteria that screen out higher-risk psychiatric histories
- Medical screening to reduce avoidable medical complications
- Supervised dosing with trained staff present throughout
- Monitoring of vital signs during dosing
- Post-session check-ins and integration sessions to monitor mood and functioning
- Clear procedures for adverse event reporting and urgent evaluation
Follow-up planning is also part of safety. Before you apply, you should think through your support system and your schedule. You may feel emotionally open after the session. You may sleep poorly for a night or two. You may feel raw, tired or reflective. You should plan for lighter obligations in the day after dosing if the protocol allows it, and you should plan transport and a quiet landing zone after the visit.
You should also plan around medication rules. Some studies require tapering or washout periods for certain medications. That should only be done under clinical supervision because abrupt changes can be risky. Your trial team will give protocol rules, but your prescribing clinician should help you evaluate the personal risk of any change.
How to talk to your clinician before you apply
You will get better outcomes from screening if you talk with your clinician before you reach out to a study site. Your clinician can help you think through safety, stability and realistic expectations.
Here are topics to cover in that conversation.
- Your diagnosis history and any past episodes of mania, psychosis or severe dissociation
- Your current medications and how changes could affect your functioning
- Your current substance use, including alcohol, cannabis and stimulants
- Your medical history, including cardiovascular history and seizure history
- Your support plan for the days after dosing
- Your goals for participating, written in plain terms that you can share with the trial team
You can also ask your clinician to help you prepare a short health timeline that you can bring into screening. That can include past treatments tried, what helped, what caused problems and what your baseline looks like on a typical week.
Near the end of your planning, it can help to understand how research groups in Massachusetts approach psilocybin science and therapeutic integration. We are Rose Hill Life Sciences, a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration, and we are based in Massachusetts.
